Open AccessImpact of HLA-B*35 subtype differences on HIV disease outcome in Mexico
Author(s) -
Claudia Juarez Molina,
Humberto Valenzuela-Ponce,
Santiago ÁvilaRíos,
Daniela Garrido-Rodríguez,
Thalia García-Téllez,
Maribel Soto-Nava,
Claudia GarcíaMorales,
Philip Goulder,
Gustavo ReyesTerán
Publication year - 2014
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000000322
Subject(s) - human leukocyte antigen , disease , immunology , hla b , allele , human immunodeficiency virus (hiv) , cohort , medicine , hla b antigens , viral disease , immunopathology , virology , biology , genetics , antigen , gene
HLA-B35 has consistently been associated with rapid HIV disease progression, particularly alleles of the Px group. As B35 is the most prevalent HLA-B in Mexico, we investigated HIV disease outcome in relation to HLA expression in a large cohort (n=976) of Mexicans. Contrary to the previous studies, no impact on viral load or CD4 cell count was observed in association with the B35 PY/Px groups. However, we observed differences in HIV disease outcome associated with specific HLA-B35 alleles.